image credit- shutterstock
CARsgen Therapeutics, a company focused on developing innovative CAR T-cell therapies, has announced that through its indirectly wholly-owned subsidiary CARsgen Diagnostics, it has signed Strategic Cooperation Agreements agreements with Shanghai Jingong Enterprise, which is a key platform enterprise in the Bay Area High-Tech Zone of Jinshan District, Shanghai.
With a total investment amount not exceeding RMB370 million, the company will establish an advanced commercial manufacturing base for CAR T-cell products in Jinshan District, Shanghai.
This move closely aligns with the commercialisation progress of the company's multiple CAR T-cell products, including the marketed product zevorcabtagene autoleucel and the CAR T-cell product satricabtagene autoleucel (CT041) for solid tumour currently in the NDA stage. It also lays the foundation for the future mass production of multiple allogeneic CAR T-cell products (such as CT0596 and CT1190B).
Under this background, enhancing CAR T-cell manufacturing capacity that meets international standards has become a core initiative to support the commercialisation of multiple products and strengthen global competitiveness. This transaction requires no significant capital expenditure from CARsgen Therapeutics in early stage, thus effectively preserving valuable cash flow for core research and development as well as market expansion. In addition, the repurchase mechanism ensures the company can fully acquire asset control after long-term operation, maintaining production stability and enhancing the flexibility of asset layout.
